Unknown

Dataset Information

0

Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.


ABSTRACT: Background:Thymidylate synthase (TS) has a predictive role in pemetrexed treatment of mesothelioma; however, additional chemoresistance mechanisms are poorly understood. Here, we explored the role of the reduced-folate carrier (RFC/SLC19A1) and proton-coupled folate transporter (PCFT/SLC46A1) in antifolate resistance in mesothelioma. Patients and methods:PCFT, RFC and TS RNA and PCFT protein levels were determined by quantitative RT-PCR of frozen tissues and immunohistochemistry of tissue-microarrays, respectively, in two cohorts of pemetrexed-treated patients. Data were analyzed by t-test, Fisher's/log-rank test and Cox proportional models. The contribution of PCFT expression and PCFT-promoter methylation to pemetrexed activity were evaluated in mesothelioma cells and spheroids, through 5-aza-2'-deoxycytidine-mediated demethylation and siRNA-knockdown. Results:Pemetrexed-treated patients with low PCFT had significantly lower rates of disease control, and shorter overall survival (OS), in both the test (N?=?73, 11.3 versus 20.1?months, P?=?0.01) and validation (N?=?51, 12.6 versus 30.3?months, P?=?0.02) cohorts. Multivariate analysis confirmed PCFT-independent prognostic role. Low-PCFT protein levels were also associated with shorter OS. Patients with both low-PCFT and high-TS levels had the worst prognosis (OS, 5.5?months), whereas associations were neither found for RFC nor in pemetrexed-untreated patients. PCFT silencing reduced pemetrexed sensitivity, whereas 5-aza-2'-deoxycytidine overcame resistance. Conclusions:These findings identify for the first time PCFT as a novel mesothelioma prognostic biomarker, prompting prospective trials for its validation. Moreover, preclinical data suggest that targeting PCFT-promoter methylation might eradicate pemetrexed-resistant cells characterized by low-PCFT expression.

SUBMITTER: Giovannetti E 

PROVIDER: S-EPMC5808668 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.

Giovannetti E E   Zucali P A PA   Assaraf Y G YG   Funel N N   Gemelli M M   Stark M M   Thunnissen E E   Hou Z Z   Muller I B IB   Struys E A EA   Perrino M M   Jansen G G   Matherly L H LH   Peters G J GJ  

Annals of oncology : official journal of the European Society for Medical Oncology 20171101 11


<h4>Background</h4>Thymidylate synthase (TS) has a predictive role in pemetrexed treatment of mesothelioma; however, additional chemoresistance mechanisms are poorly understood. Here, we explored the role of the reduced-folate carrier (RFC/SLC19A1) and proton-coupled folate transporter (PCFT/SLC46A1) in antifolate resistance in mesothelioma.<h4>Patients and methods</h4>PCFT, RFC and TS RNA and PCFT protein levels were determined by quantitative RT-PCR of frozen tissues and immunohistochemistry o  ...[more]

Similar Datasets

| S-EPMC2716086 | biostudies-literature
| S-EPMC4794783 | biostudies-literature
| S-EPMC7226238 | biostudies-literature
| S-EPMC3799626 | biostudies-literature
| S-EPMC3602806 | biostudies-literature
| S-EPMC7434895 | biostudies-literature
| S-EPMC3885236 | biostudies-literature
| S-EPMC2711648 | biostudies-literature
| S-EPMC5761628 | biostudies-literature
| S-EPMC8601550 | biostudies-literature